Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

NCT00193245 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Topotecan
DRUG: Docetaxel

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]
[object Object]